Rimonabant Acomplia

The Zimulti Acomplia Report

Now that a promising new prescription weight loss drug, rimonabant, it is today available in the U.K., Germany and 44 other countries, the launch of the most anticipated weight-loss Drug since Fen-phen is generating a great deal of excitement among millions of obese people  and seriously overweight Americans and Europeans.
The medication, sold in Europe as Acomplia, may ultimately be sold in the United States as Zimulti — but that day seems to be  several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects.
The Rimonabant Zimulti Acomplia Report, updated every day, will track the continuing efforts of Sanofi Avensis to get Rimonabant approved for sale on the U.S. market The Zimulti Acomplia Report also will provide news,informations and reviews about  rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.
Side effects of Acomplia Rimonabant were described as minor and temporary, the most frequent    being diarrhea, nausea, vomiting and dizziness. More severe anticipated side effects, especially    depression, did not materialize. it caused  nausea in 13% of patients, vs. in 4% of those who got    placebo.

The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European regulators are expected to act on Sanofi-Aventis’ application to bring the drug to market.

In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo.

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

Announcement of the results of the RIO-Diabetes trial is slated for a symposium on “Late-Breaking Clinical Trials” scheduled to be held at 2 pm PDT June 12th.

Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier — RIO-North America, RIO-Europe and RIO-Lipids.

The fact that the results are going to be presented at the highest-profile symposium at the American Diabetes Association meeting — only weeks after Sanofi filed for approval of the drug with the U.S. Food and Drug Administration and European regulators — also strongly suggests more positive news is forthcoming.

More related articles: Acomplia news report

                                     Rimonabant acomplia competitor